08 December 2023>: Clinical Research
Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer
Wei Tao 1DEF* , Weiqi Wang 1CDF , Jingfang Zhai 2BCF , Linlin Guo 1ABFDOI: 10.12659/MSM.940545
Med Sci Monit 2023; 29:e940545
Figure 3 Progression-free survival between patients sensitive to neoadjuvant chemotherapy and patients insensitive to neoadjuvant chemotherapy. Progression-free survival: survival of patients after adjuvant chemotherapy without recurrence or detection of disease. χ2 test was used for statistical analysis.